In cGMP peptide API production for an orally administered long-chain acylated GLP-1 receptor agonist formulated as enteric-coated tablets and capsules, Fmoc-amino acid building blocks are selected with residual D-enantiomer content below 0.10% by chiral HPLC and residual TFA below 0.05% by ion chromatography; the solid raw material is pre-dried in vacuum ovens at 35–40°C for 12–18 h when ambient RH exceeds 60% because water uptake above 0.5% w/w accelerates premature hydration of uronium coupling reagents in DMF. The addition ratio is fixed at 3.5–4.0 molar equivalents relative to resin-bound free amino groups on a 2-chlorotrityl chloride resin loaded at 0.65 mmol/g; pre-activation with HOBt/DIC at 0–5°C for 5–10 min reduces oxazolone-mediated racemization, and the activated Fmoc-amino acid solution is charged through a 0.45 μm polypropylene filter cartridge into the SPPS reactor at a DMF slurry ratio of 8–10 mL/g resin. Agitation at 55–65 rpm in a 50 L jacketed glass reactor with PTFE-coated thermowell maintains reactor contents at 22±2°C; coupling endpoints are monitored by the ninhydrin Kaiser test and, for secondary amines, by the chloranil test, and incomplete couplings receive a second addition of 1.2 equivalents fresh Fmoc-amino acid plus HATU/DIPEA in DMF. Fmoc removal uses 20% piperidine in DMF v/v with two 5 min cycles and one 10 min wash; the dibenzofulvene-piperidine adduct absorbance at 301 nm is converted to loading using the extinction coefficient 7,800 L mol⁻¹ cm⁻¹ to confirm residual Fmoc on resin is ≤0.02 mmol/g before the next coupling. After chain assembly, the peptide is cleaved from the resin with TFA/TIS/water 95:2.5:2.5 v/v over 2–3 h at 20–25°C, precipitated in cold methyl tert-butyl ether at −20°C, and dried under reduced pressure; preparative reversed-phase HPLC with a 10 cm C18 column and acetonitrile/0.1% TFA gradient delivers the peptide acetate salt, which is then exchanged to the chloride or acetate counterion via ion-exchange chromatography. Terminal product types are enteric-coated tablets with a polymer coating that withstands 2 h at pH 1.2 per USP <2040>, hypromellose capsules containing spray-dried peptide granules with an absorption enhancer, and single-dose oral granules in sachets that are dispersed in water immediately before administration. Compliance standards for the oral peptide API and dosage form include ICH Q7 Section 7.3 for cleaning validation, ICH Q3D and USP <232>/<233> for elemental impurities, USP <467> for residual piperidine and methyl tert-butyl ether, Ph. Eur. 2.2.46 for HPLC suitability, and USP <621> for chromatographic purity; residual Fmoc-glycine and Fmoc-dipeptide impurities are controlled at ≤0.10% total by area normalisation because these process-related impurities carry the Fmoc chromophore and can co-elute with late-eluting peptide impurities on C18 columns unless orthogonal analysis at 301 nm is used.

What Limits Fmoc-Amino Acid Molar Excess in 50 mmol Automated SPPS of a 16-Residue Injectable Peptide?

Automated Fmoc SPPS of a 16-residue peptide API intended for sterile injectable solution faces a stoichiometry-dependent purity cliff-edge: below 2.2 molar equivalents of Fmoc-amino acid relative to resin substitution, incomplete acylation generates deletion peptide impurities that require multistep preparative HPLC rework; above 5.0 equivalents, excess activated amino acid raises racemization and by-product formation without improving coupling yield. The design space is established using a 50 mmol automated peptide synthesizer with 0.1 mmol resin cartridge and microwave-assisted coupling at 75°C for 4 min, or conventional room-temperature coupling at 22°C for 60 min; agitation and nitrogen sparge cycles are controlled by the instrument. Fmoc-amino acids are dissolved in DMF to 0.2 M and activated in situ with HBTU/DIPEA at 1:1:2 molar ratio relative to amino acid. The addition ratio is normally 3.0 equivalents for unhindered residues and 4.5 equivalents for Fmoc-His(Trt)-OH and Fmoc-Arg(Pbf)-OH; double couplings with 2 × 2.5 equivalents are programmed for N-methyl amino acids and coupling to secondary amines. For Asp-Gly sequences, piperidine deprotection can induce aspartimide formation, so 0.1 M HOBt in piperidine or 2% DMSO is added to suppress aspartimide during Fmoc removal. Coupling completion is measured by a quantitative ninhydrin assay at 570 nm; typical residual free amines are ≤0.3 μmol/g after single coupling. Because published datasets for this exact sequence and resin substitution are limited, the lower and upper stoichiometric boundaries above were established during laboratory-scale reaction calorimetry and are reported as process development acceptance ranges rather than regulatory release limits. Process deviation data from pilot-scale runs indicate that reducing molar excess to 1.8 equivalents increases des-Gly deletion content from 0.08% to 1.7% by HPLC area percent, which triggers batch rejection under a specification limit of ≤0.5% for any individual deletion peptide. Raising molar excess to 6.0 equivalents increases D-amino acid-related diastereomer content from 0.05% to 0.9%, failing the API criterion of ≤0.3% total D-isomer. Downstream production includes cleavage with TFA/TIS/water 90:5:5 v/v, precipitation in MTBE at −20°C, preparative HPLC, counterion exchange to acetate, and sterile filtration through 0.22 μm PVDF. Terminal product types include single-dose vials of peptide solution for subcutaneous injection and lyophilized powder for reconstitution with sterile water for injection. Compliance standards include USP <85> for bacterial endotoxins, USP <788> for particulate matter, USP <71> for sterility, and ICH Q3C Table 2 for residual DMF and piperidine.

During technology transfer of a 20-residue anticoagulant peptide API to a 200 L SPPS reactor, resin bed compression at slurry ratios below 7 mL/g caused insufficient diffusion of Fmoc-Arg(Pbf)-OH into the lower resin layer, leaving deletion peptides at 1.9% by HPLC; this was corrected by increasing the addition ratio to 4.0 molar equivalents and pre-swelling the resin in DCM for 30 min before washing with DMF. The peptide chain is assembled on Rink amide AM resin at 0.42 mmol/g to yield a C-terminal amide. Coupling is performed with Fmoc-amino acid/HBTU/DIPEA 4:4:8 in DMF, with a nitrogen-overlay agitation rate of 40–50 rpm in a 200 L glass-lined reactor. Fmoc deprotection uses 20% piperidine; the reactor is washed with DMF until the UV detector return at 301 nm is below 0.05 AU. Cleavage with TFA/TIS/H₂O 95:2.5:2.5 at 25°C for 3 h gives crude peptide, which is precipitated, dried, and purified by preparative HPLC. The purified peptide is concentrated by rotary evaporation at ≤35°C and lyophilized with 0.5% acetic acid as bulk API. For injectable product, the API is dissolved in Water for Injection, pH adjusted to 5.0–5.5 with 0.1 N HCl or 0.1 N NaOH, sterile-filtered, and filled as a frozen liquid for lyophilization. Terminal product types are single-dose vials containing lyophilized powder for injection, and ready-to-use sterile solution in 2 mL vials. Compliance standards include USP <85> for endotoxin ≤10 EU/mg, USP <790> for visible particulates, USP <788> for subvisible particulate counts, Ph. Eur. 2.2.32 for loss on drying, ICH Q7 Section 19 for batch release, and ICH Q3D for elemental impurities; residual TFA is controlled by ion chromatography to ≤0.1%.

Resin Substitution, Bulk Density, and Fmoc Loading Drift in Depot Microsphere Granulation

For a GnRH agonist decapeptide API incorporated into PLGA-based depot microspheres, Fmoc-amino acids are charged at 3.0 equivalents relative to a Rink amide AM resin loading of 0.40–0.45 mmol/g; the low resin loading reduces interchain aggregation of hydrophobic side-chain-protected residues, but requires solvent volume of 12 mL/g resin to maintain suspension homogeneity. Coupling with HBTU/DIPEA at 25°C for 60 min and recoupling at 1.5 equivalents for Fmoc-Leu-OH and Fmoc-Trp(Boc)-OH lowers racemization and tryptophan tert-butyl side reactions. After assembly, peptide is cleaved with TFA/TIS/EDT 90:5:5 to minimize cysteine alkylation; crude purity is measured by UPLC at 210 nm. The purified acetate salt is converted to a more hydrophobic salt for PLGA encapsulation; bulk drug is dissolved in glacial acetic acid and spray-dried with 0.5% w/w Poloxamer 188 to improve syringeability upon reconstitution. Microspheres are produced by a single emulsion solvent evaporation method using PLGA 75:25 dissolved in dichloromethane; the peptide powder is suspended at 10–20% w/w relative to polymer, injected into a 1% w/v polyvinyl alcohol continuous phase under high-shear mixing at 5,000–8,000 rpm, and hardened at 20–25°C for 3–4 h. Terminal product types include single-dose kits containing lyophilized microspheres for intramuscular injection, multi-dose depot suspensions supplied as powder and diluent, and granules for subcutaneous implantation if combined with a biodegradable polymer matrix. Compliance standards include USP <788> for particulate matter in injectable suspensions, USP <790> for visible particulates, USP <85> for bacterial endotoxins, USP <71> for sterility, ICH Q3C for dichloromethane residual solvent ≤600 ppm as a Class 2 solvent, and ISO 13408-1 for aseptic processing; residual PLGA-related lactide and glycolide monomers are monitored by USP <621> with limits aligned to the drug product specification.

When Orthogonal Side-Chain Deprotection Requires Low-Acid Cleavage from 2-Chlorotrityl Resin

Orthogonal synthesis of a macrocyclic peptide API with a C-terminal lactam bridge requires Fmoc-amino acid derivatives whose side-chain protecting groups remain intact during resin cleavage; Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Mtt)-OH, and Fmoc-Gly-OH are coupled to 2-chlorotrityl chloride resin at 0.82 mmol/g substitution. Initial loading of the first Fmoc-amino acid uses 0.8 equivalents relative to the resin in DCM with DIPEA 3 equivalents; remaining active chloride is capped with methanol 0.8 mL/g resin for 30 min. Chain elongation uses Fmoc-amino acid/HATU/DIPEA 4:4:8 in DMF at 20°C for 45 min, with Fmoc removal in 20% piperidine and UV monitoring at 301 nm. After assembly, the fully protected peptide is cleaved with 20% 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) in DCM over 30 min at 25°C; the use of low acid avoids premature removal of the Mtt and OtBu groups. The resulting protected peptide is precipitated in cold diethyl ether, washed, and cyclized in DMF at 0.5 mM with HATU/DIPEA 1.2:3 for 16 h. Side-chain deprotection then proceeds in TFA/TIS/water 95:2.5:2.5 v/v for 2 h; the crude cyclic peptide is purified by preparative HPLC with mass-directed fraction collection. Terminal product types include sterile lyophilized powder in vials reconstituted before intravenous infusion, and delayed-release capsules containing the cyclic peptide absorbed after enteric coating. Compliance standards include ICH Q7 Section 7.4 for recovery and purification, USP <621> for HPLC purity, USP <921> for water content ≤2.0% in lyophilized API, ICH Q3C for HFIP and DCM residuals, and USP <85> for endotoxin ≤5.0 EU/mg if the product is injectable; residual Fmoc-cyclic intermediate is controlled as an unreacted intermediate with a specification of ≤0.15% by HPLC area percent.

Process-validation batches of a 31-residue peptide API for injectable sustained-release formulation demand impurity markers that cannot be obtained from crude batch enrichment alone; Fmoc-amino acid building blocks are therefore used in a parallel small-scale SPPS to synthesize des-amido, D-amino acid, and Fmoc-dipeptide process impurities under controlled addition ratios. For synthesis of impurity markers, Fmoc-amino acid is charged at 2.0 molar equivalents with HBTU/DIPEA to generate incomplete coupling products, or at 10 equivalents with DIC in DMF at 40°C to force epimerization; crude impurity purities are enriched by preparative HPLC and characterised by high-resolution mass spectrometry. The resulting impurity standards are used to validate the HPLC peak purity method for the API per ICH Q2(R2), with linearity from 0.05% to 1.0% and recovery between 90–110%. In routine production, Fmoc-amino acid addition ratio for the peptide API is fixed at 3.5 equivalents and any raw material lot with Fmoc-chloride residual above 0.30% is rejected because it generates Fmoc-dipeptide impurity during the first coupling. Compliance standards include USP <1086> for impurity qualification, USP <621> for peak purity, ICH Q3A/Q3B for impurity thresholds, and Ph. Eur. 2.2.46 for HPLC system suitability. Terminal product types served by this impurity program are injectable peptide vials, peptide capsules, and granules for oral suspension.